BAYTRIL PIGLET DOSER 0.5% ORAL SOLUTION

Summary of Product characteristics

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Baytril Piglet Doser 0.5% Oral Solution
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Oral Solution.
Clear aqueous solution
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Piglets.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
The product is for use in the treatment of diseases of the respiratory
and alimentary tracts of bacterial or mycoplasmal
origin (e.g. pasteurellosis, mycoplasmosis, coli-bacillosis,
coli-septicaemia and salmonellosis), and multifactorial diseases
such as atrophic rhinitis and enzootic pneumonia, where clinical
experience, supported where possible by sensitivity testing
of the casual organism, indicates enrofloxacin as the drug of choice.
4.3 CONTRAINDICATIONS
Should not be used for prophylaxis.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None known.
Active Constituents
mg per ml
Enrofloxacin
5.0
Relevant Constituents of the Excipient
Benzyl Alcohol
14.0
For full list of excipients see section 6.1
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_8_
_/_
_0_
_4_
_/_
_2_
_0_
_1_
_7_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_6_
_6_
_2_
_4_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Official and local antimicrobial policies should be taken into account
when the product is used.
Fluoroquinolones should be reserved for the treatment of clinical
conditions which have responded poorly, or are
exp
                                
                                Read the complete document